CTO-1681 is under clinical development by CytoAgents and currently in Phase II for Cytokine Release Syndrome (Cytokine Storm). According to GlobalData, Phase II drugs for Cytokine Release Syndrome (Cytokine Storm) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CTO-1681’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CTO-1681 overview

CTO-1681 is under development for the treatment of influenza A virus subtype H5N1 and H1N1 infections, COVID-19 associated cytokine release syndrome (cytokine storm) and cytokine release syndrome in oncology. The drug candidate is a small molecule, it is administered orally. It is a beraprost isomer (isomer A), which acts by targeting G-protein coupled receptor (GPCR) and nuclear factor kappa B (NF-kB). It was under development for the treatment of COVID-19 disease.

CytoAgents overview

CytoAgents is a biotechnology company that engaged in the development of innovative pharmaceutical products. The company is headquartered in United States.

For a complete picture of CTO-1681’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.